Discontinuation of beta blocker therapy in patients with cardiogenic shock resulted in increased 1-month all-cause mortality (P=0.03) and a trend toward increased 1-year mortality.
Observational (n=772)
Yes
Does beta blocker use (continuation or early introduction) improve 1-month and 1-year all-cause mortality in patients with cardiogenic shock?
Discontinuation of beta blockers within 24 hours of cardiogenic shock is associated with increased 1-month mortality, suggesting they should be continued when possible.
p-value: p=0.03
BACKGROUND: Beta blockers (BBs) are a cornerstone for patients with heart failure (HF) and ventricular dysfunction. However, their use in patients recovering from a cardiogenic shock (CS) remains a bone of contention, especially regarding whether and when to reintroduce this class of drugs. METHODS: FRENSHOCK is a prospective multicenter registry including 772 CS patients from 49 centers. Our aim was to compare outcomes (1-month and 1-year all-cause mortality) between CS patients taking and those not taking BBs in three scenarios: (1) at 24 h after CS; (2) patients who did or did not discontinue BBs within 24 h; and (3) patients who did or did not undergo the early introduction of BBs. RESULTS: = 0.03) and a trend to lower 1-year mortality. No reduction in outcomes was observed in patients who underwent an early introduction of BB therapy. CONCLUSIONS: BBs are drugs of first choice in patients with HF and should also be considered early in patients with CS. In contrast, the discontinuation of BB therapy resulted in increased 1-month all-cause mortality and a trend toward increased 1-year all-cause mortality.
Cardelli et al. (Mon,) conducted a observational in Cardiogenic shock (n=772). Beta blockers vs. Not taking or discontinuing beta blockers was evaluated on 1-month and 1-year all-cause mortality (p=0.03). Discontinuation of beta blocker therapy in patients with cardiogenic shock resulted in increased 1-month all-cause mortality (P=0.03) and a trend toward increased 1-year mortality.